{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:45:07Z","timestamp":1786373107153,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Prescription patterns for hemodialysis patients with secondary hyperparathyroidism have varied widely since market introduction of cinacalcet. This study examined associations between prescription patterns and subsequent laboratory values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>Using a Mineral and Bone Disorder Outcomes Study for Japanese CKD Stage 5D Patients subcohort, 1716 prevalent hemodialysis patients (4048 sets for repeated measures between January 2008 and July 2009) with an intact parathyroid hormone (iPTH) level &gt;180 pg\/ml who used intravenous vitamin D receptor activator (VDRA) without cinacalcet were selected. Prescription patterns were defined based on cinacalcet administration (starting or not) and VDRA dosage change (decreased [&lt;\u221225%], stable [\u221225% to 25%], or increased [&gt;25%]). Proportion differences (PDs) were determined for decreasing iPTH levels by at least one category (&lt;180, 180\u2013299, 300\u2013499, and \u2265500 pg\/ml) and for achieving target phosphorus (3.5\u20136.0 mg\/dl) and calcium (8.4\u201310.0 mg\/dl) levels, adjusting for potential confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The starting cinacalcet and increased VDRA patterns were associated with decreasing iPTH levels (PD, 0.25 and 0.13; 95% confidence intervals [95% CIs], 0.19\u20130.31 and 0.09\u20130.17, respectively); combination use had an additive association (PD, 0.34; 95% CI, 0.20\u20130.42). The starting cinacalcet and decreased VDRA combination was associated with simultaneously achieving target phosphorus (PD, 0.12; 95% CI: 0.04\u20130.20) and calcium (PD, 0.09; 95% CI, 0.01\u20130.17) levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Certain combinations of cinacalcet and VDRA were associated with decreasing iPTH and achieving targets for phosphorus and calcium. Combinations may prove advantageous versus VDRA alone in managing secondary hyperparathyroidism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.13081211","type":"journal-article","created":{"date-parts":[[2012,7,20]],"date-time":"2012-07-20T10:08:07Z","timestamp":1342778887000},"page":"1473-1480","source":"Crossref","is-referenced-by-count":30,"title":["Prescription Patterns and Mineral Metabolism Abnormalities in the Cinacalcet Era"],"prefix":"10.2215","volume":"7","author":[{"given":"Masafumi","family":"Fukagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Fukuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20230811","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2215\/CJN.05241008","article-title":"Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006.","volume":"4","author":"St Peter","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R2-14-20230811","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/ndt\/gfl840","article-title":"Implementation of \u2018K\/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease\u2019 after the introduction of cinacalcet in a population of patients on chronic haemodialysis.","volume":"22","author":"Arenas","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R3-14-20230811","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.2215\/CJN.11501210","article-title":"Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: Associations with changing practice patterns.","volume":"6","author":"Akizawa","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R4-14-20230811","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: Assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism.","volume":"3","author":"Messa","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R5-14-20230811","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results.","volume":"3","author":"Fishbane","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R6-14-20230811","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study.","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R7-14-20230811","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney Int"},{"key":"R8-14-20230811","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"R9-14-20230811","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfm534","article-title":"Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients.","volume":"23","author":"Fukagawa","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R10-14-20230811","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.2010.167","article-title":"Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients.","volume":"78","author":"Block","year":"2010","journal-title":"Kidney Int"},{"key":"R11-14-20230811","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int"},{"key":"R12-14-20230811","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ki.2008.166","article-title":"Calcimimetics in chronic kidney disease: Evidence, opportunities and challenges.","volume":"74","author":"Evenepoel","year":"2008","journal-title":"Kidney Int"},{"key":"R13-14-20230811","doi-asserted-by":"crossref","first-page":"c41","DOI":"10.1159\/000212102","article-title":"Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.","volume":"112","author":"Wilkie","year":"2009","journal-title":"Nephron Clin Pract"},{"key":"R15-14-20230811","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","article-title":"Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.","volume":"70","author":"Jadoul","year":"2006","journal-title":"Kidney Int"},{"key":"R16-14-20230811","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ajkd.2005.09.024","article-title":"PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.","volume":"47","author":"Danese","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R17-14-20230811","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R18-14-20230811","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"R19-14-20230811","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS).","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R20-14-20230811","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1744-9987.2007.00540.x","article-title":"Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan.","volume":"12","author":"Nakai","year":"2008","journal-title":"Ther Apher Dial"},{"key":"R24-14-20230811","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/ki.2010.108","article-title":"International trends in erythropoietin use and hemoglobin levels in hemodialysis patients.","volume":"78","author":"McFarlane","year":"2010","journal-title":"Kidney Int"},{"key":"R25-14-20230811","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1744-9987.2010.00906.x","article-title":"Mineral and bone disorders outcomes study for Japanese chronic kidney disease stage 5D patients: Rationale and study design.","volume":"15","author":"Fukuhara","year":"2011","journal-title":"Ther Apher Dial"},{"key":"R26-14-20230811","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000327654","article-title":"Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: Baseline data from the MBD-5D.","volume":"33","author":"Fukagawa","year":"2011","journal-title":"Am J Nephrol"},{"key":"R27-14-20230811","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/ndt\/gfg144","article-title":"Influence of PTH assay methodology on differential diagnosis of renal bone disease.","volume":"18","author":"Reichel","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R28-14-20230811","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/bmj.4.5893.643","article-title":"Interpretation of serum calcium in patients with abnormal serum proteins.","volume":"4","author":"Payne","year":"1973","journal-title":"BMJ"},{"key":"R29-14-20230811","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z","article-title":"Extending the simple linear regression model to account for correlated responses: An introduction to generalized estimating equations and multi-level mixed modelling.","volume":"17","author":"Burton","year":"1998","journal-title":"Stat Med"},{"key":"R30-14-20230811","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/aje\/kwf215","article-title":"Statistical analysis of correlated data using generalized estimating equations: An orientation.","volume":"157","author":"Hanley","year":"2003","journal-title":"Am J Epidemiol"},{"key":"R31-14-20230811","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/sim.4780111406","article-title":"An overview of methods for the analysis of longitudinal data.","volume":"11","author":"Zeger","year":"1992","journal-title":"Stat Med"},{"key":"R33-14-20230811","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/ki.2008.645","article-title":"The effect of joint exposures: Examining the presence of interaction.","volume":"75","author":"de Mutsert","year":"2009","journal-title":"Kidney Int"},{"key":"R34-14-20230811","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2215\/CJN.04520908","article-title":"Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and\/or vitamin D derivatives.","volume":"4","author":"Dr\u00fceke","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R35-14-20230811","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options.","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R36-14-20230811","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1744-9987.2011.00997.x","article-title":"Influence of the assay for measuring serum albumin on corrected total calcium in chronic hemodialysis patients.","volume":"15","author":"Kato","year":"2011","journal-title":"Ther Apher Dial"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201209000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:23Z","timestamp":1786369343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201209000-00014"}},"subtitle":["Results from the MBD-5D Study"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.13081211","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}